The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Almirall Hermal GmbH; BioNTech; Bristol-Myers Squibb; Immunocore; Merck; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Speakers' Bureau - Almirall Hermal GmbH; BioNTech; Bristol-Myers Squibb; Immunocore; Kyowa Kirin; Merck; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Travel, Accommodations, Expenses - Almirall Hermal GmbH; BioNTech; Bristol-Myers Squibb; Immunocore; Kyowa Kirin; Merck; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
John M. M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Magnolia Innovation; Merck; Natera; OncoCyte; OncoSec; PATHAI; Pfizer; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron
 
Christoph Hoeller
Honoraria - Bristol Myers Squibb Foundation; MSD; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Almirall Hermal GmbH; Bristol Myers Squibb Foundation; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi
Research Funding - Amgen (Inst); Bristol Myers Squibb Foundation (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation (Inst); MSD (Inst); Pierre Fabre (Inst); Sanofi (Inst)
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma; Ultimovacs
Speakers' Bureau - Novartis; Pierre Fabre
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; Instil Bio; NexImmune; OncoC4
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Protean Biodiagnostics; Roche; Sellas Life Sciences; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Janis M. Taube
Stock and Other Ownership Interests - Akoya Biosciences
Consulting or Advisory Role - Akoya Biosciences; AstraZeneca; Bristol-Myers Squibb; Compugen; Lunaphore Technologies; Merck
Research Funding - Akoya Biosciences (Inst); Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - image processing of multiplex IF/IHC slides (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck
Other Relationship - Akoya Biosciences
 
Peter Mohr
Honoraria - Beiersdorf; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Carmen Loquai
No Relationships to Disclose
 
Caroline Dutriaux
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Vanna Chiarion-Sileni
Speakers' Bureau - Merck Sharp & Dohme; Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre
 
Daniel J. Tenney
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene
 
Sonia Dolfi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Hao Tang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Corey Ritchings
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Maurice Lobo
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Federico Campigotto
Employment - Bristol-Myers Squibb; Genentech (I); Gilead Sciences (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; Genentech (I); Gilead Sciences (I)
 
Wenjia Wang
Employment - Flatiron Health (I)
Stock and Other Ownership Interests - Roche (I)
 
Brian Gastman
Stock and Other Ownership Interests - Castle Biosciences
Consulting or Advisory Role - Castle Biosciences; Quest Imaging
Speakers' Bureau - Castle Biosciences
Research Funding - Alkermes; Instil Bio; Merck; NeoImmuneTech; Quest Imaging
Travel, Accommodations, Expenses - Alkermes
 
Michele Del Vecchio
Consulting or Advisory Role - Bristol Myers Squibb; Immunocore; Merck; Novartis; Pierre Fabre